Trends in non-Hodgkin lymphoma mortality: global, regional, and national insights from 1990 to 2021.

IF 2.3 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2025-06-26 DOI:10.1080/17474086.2025.2522959

Fangna Gu, Li Zhang

{"title":"Trends in non-Hodgkin lymphoma mortality: global, regional, and national insights from 1990 to 2021.","authors":"Fangna Gu, Li Zhang","doi":"10.1080/17474086.2025.2522959","DOIUrl":null,"url":null,"abstract":"Background: Non-Hodgkin Lymphoma (NHL) is a group of hematological cancers with significant global mortality. Despite advances in treatment, mortality disparities persist across age, sex, region, and socioeconomic status, underscoring the need for a deeper understanding of global trends.Research design and methods: Data from the Global Burden of Disease Study covering 204 countries between 1990 and 2021 were analyzed. The data were stratified by sex, age, and Socio-Demographic Index (SDI). Trends were assessed using the Estimated Annual Percentage Change (EAPC), and correlations with SDI were evaluated.Results: From 1990 to 2021, global NHL deaths increased from 146,657 to 267,061, and death rates rose from 2.75 to 3.38 per 100,000 (EAPC: 0.51). Males and individuals aged 75 and older had higher mortality rates. High-SDI regions, including High-income North America (8.49 per 100,000) and High-income Asia Pacific (9.60 per 100,000), had the highest rates. Middle-SDI regions showed the most significant increases, while low-SDI regions experienced declines. Japan had a sharp rise in mortality (EAPC: 3.03), while Ethiopia had a decline (EAPC: -2.09).Conclusion: NHL mortality increased globally from 1990 to 2021, with higher burdens in males and older adults. The fastest increases were observed in middle-SDI regions, reflecting healthcare disparities.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-10"},"PeriodicalIF":2.3000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2522959","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Non-Hodgkin Lymphoma (NHL) is a group of hematological cancers with significant global mortality. Despite advances in treatment, mortality disparities persist across age, sex, region, and socioeconomic status, underscoring the need for a deeper understanding of global trends.

Research design and methods: Data from the Global Burden of Disease Study covering 204 countries between 1990 and 2021 were analyzed. The data were stratified by sex, age, and Socio-Demographic Index (SDI). Trends were assessed using the Estimated Annual Percentage Change (EAPC), and correlations with SDI were evaluated.

Results: From 1990 to 2021, global NHL deaths increased from 146,657 to 267,061, and death rates rose from 2.75 to 3.38 per 100,000 (EAPC: 0.51). Males and individuals aged 75 and older had higher mortality rates. High-SDI regions, including High-income North America (8.49 per 100,000) and High-income Asia Pacific (9.60 per 100,000), had the highest rates. Middle-SDI regions showed the most significant increases, while low-SDI regions experienced declines. Japan had a sharp rise in mortality (EAPC: 3.03), while Ethiopia had a decline (EAPC: -2.09).

Conclusion: NHL mortality increased globally from 1990 to 2021, with higher burdens in males and older adults. The fastest increases were observed in middle-SDI regions, reflecting healthcare disparities.

查看原文本刊更多论文

非霍奇金淋巴瘤死亡率趋势：1990年至2021年全球、地区和国家洞察

背景：非霍奇金淋巴瘤（NHL）是一组具有显著全球死亡率的血液学癌症。尽管在治疗方面取得了进展，但不同年龄、性别、地区和社会经济地位的死亡率差异仍然存在，这突出表明需要更深入地了解全球趋势。研究设计和方法：分析了1990年至2021年间覆盖204个国家的全球疾病负担研究数据。数据按性别、年龄和社会人口指数（SDI）分层。使用估计年度百分比变化（EAPC）评估趋势，并评估与SDI的相关性。结果：从1990年到2021年，全球NHL死亡人数从146,657人增加到267,061人，死亡率从每10万人2.75人上升到3.38人（EAPC: 0.51）。男性和75岁及以上的人死亡率更高。高sdi地区，包括北美高收入地区（每10万人中有8.49人）和亚太高收入地区（每10万人中有9.60人）的比率最高。中sdi地区的增长最为显著，而低sdi地区则出现了下降。日本的死亡率急剧上升（EAPC: 3.03），而埃塞俄比亚的死亡率下降（EAPC: -2.09）。结论：从1990年到2021年，全球NHL死亡率上升，男性和老年人的负担更高。增长最快的是sdi中部地区，反映了医疗保健方面的差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.